gemcitabine/SU5416

Known as: dFdC/SU-5416 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2011
0120022011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
AIM To explore the effect of VEGF inhibitor SU5416 on podocytopathy of rats with type I diabetic nephropathy. METHODS Thirty… (More)
Is this relevant?
2007
2007
Potential prodrugs of inhibitors of VEGF-induced angiogenesis have been investigated. The prodrug systems studied were the 4… (More)
Is this relevant?
Review
2006
Review
2006
SU5416, 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, is a potent inhibitor of vascular endothelial growth… (More)
Is this relevant?
2005
2005
Vascular endothelial growth factor (VEGF) is a potent stimulant of angiogenesis. SU5416, is a small molecule tyrosine kinase… (More)
  • table 2
  • table 1
  • table 3
  • table 4
Is this relevant?
2004
2004
SU5416 is a selective inhibitor of vascular endothelial growth factor (VEGF) receptor, which plays a major role in vascular… (More)
Is this relevant?
2002
2002
Chronically hypoxic rats (exposed to 5000 m elevation for 3 weeks) develop pulmonary hypertension (PH) that is reversed upon… (More)
Is this relevant?